Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Novo Nordisk A/S Class B (NOVOb)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
795.0 +8.7    +1.11%
10:59:49 - Closed. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  Denmark
ISIN:  DK0060534915 
S/N:  1742564000
  • Volume: 1,272,602
  • Bid/Ask: 0.0 / 0.0
  • Day's Range: 784.7 - 799.4
Novo Nordisk B 795.0 +8.7 +1.11%

NOVOb Historical Data

 
Get free historical data for NOVOb. You'll find the closing price, open, high, low, change and %change of the Novo Nordisk A/S Class B Stock for the selected range of dates. The data can be viewed in daily, weekly or monthly time intervals. At the bottom of the table you'll find the data summary for the selected range of dates.
Time Frame:
05/30/2022 - 06/27/2022
 
Download Data
Date Price Open High Low Vol. Change %
Jun 27, 2022 795.0 799.4 799.4 784.7 1.28M 1.11%
Jun 24, 2022 786.3 764.5 791.4 764.5 1.48M 3.07%
Jun 23, 2022 762.9 758.3 763.2 749.2 1.36M 0.18%
Jun 22, 2022 761.5 758.9 766.8 755.4 1.67M 0.03%
Jun 21, 2022 761.3 765.9 775.6 758.9 1.34M 0.00%
Jun 20, 2022 761.3 748.5 765.5 748.5 860.60K 1.90%
Jun 17, 2022 747.1 744.8 762.9 744.8 4.02M 0.52%
Jun 16, 2022 743.2 753.3 760.7 740.6 1.52M -2.09%
Jun 15, 2022 759.1 755.4 765.9 750.5 2.17M 0.49%
Jun 14, 2022 755.4 771.9 782.8 752.7 1.92M -1.92%
Jun 13, 2022 770.2 782.2 786.3 769.2 1.76M -1.96%
Jun 10, 2022 785.6 793.2 793.3 780.5 1.06M -1.06%
Jun 09, 2022 794.0 799.5 807.8 792.9 1.56M -1.77%
Jun 08, 2022 808.3 805.6 809.4 796.8 1.59M 0.84%
Jun 07, 2022 801.6 790.0 802.5 786.9 2.08M 2.87%
Jun 03, 2022 779.2 777.7 784.8 775.0 1.43M 1.19%
Jun 02, 2022 770.0 771.2 778.8 765.4 1.21M 0.08%
Jun 01, 2022 769.4 763.8 772.5 754.0 2.01M 0.22%
May 31, 2022 767.7 764.8 775.2 752.6 6.83M -0.32%
May 30, 2022 770.2 753.6 783.0 752.6 1.87M 4.28%
Highest: 809.4 Lowest: 740.6 Difference: 68.8 Average: 772.5 Change %: 7.6
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

NOVOb Comments

Write your thoughts about Novo Nordisk A/S Class B
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Toby Brunt
Toby Brunt Apr 19, 2022 5:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
Reply
0 0
Report
Sandy SS
Sandy SS Feb 09, 2022 8:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New Target 825 by EOM
Reply
1 0
Report
Sandy SS
Sandy SS Feb 09, 2022 8:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New Target 825
Reply
0 0
Report
Terrible Investor
TerribleInvestor Nov 25, 2021 5:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Consolidating nicely for leg up to 850!🌟
Reply
1 0
Report
Ralf Adams
Ralf Adams Feb 11, 2021 4:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
Reply
0 1
Report
Candy Man
Candy Man Jan 14, 2021 4:16PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
Reply
1 0
Report
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
bullish??
Reply
2 0
Report
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
No. Funds are selling. Time to wait to go long...
Reply
0 0
Report
White Wizard
White Wizard May 26, 2020 7:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Perfect opportunity to make short,,
Reply
0 1
Report
Wassim Khayata
Wassim Khayata May 26, 2020 7:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
can you explain why please?
Reply
2 0
Report
Jeff Heimann
Jeff Heimann May 26, 2020 7:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
No explaning? 🤷
Reply
0 0
Report
Tommi Nuutinen
Tommi Nuutinen May 26, 2020 7:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
because he has no explanation. Novo nordisk is a soli long-term stock. I know a lot about opioid treatments, and methadon is changing to lipo-methadon, wich has really only one competitor on the global field. That competitor is Camurus AB with their product buvidol. I tecommend to all investors to buy and HOLD for these two companies, because there is no other options for a opioid-replacement-care, except Suboxone, and that is going to be replaced Lipo-methadon or Buvidol, at least here in Finland. Suboxone is manufactured for Indivor Inc, by Aquestive Therapeutics, if someone wants to do a little research.
Reply
2 0
Report
Hairol Azhar Abdul Kadir
Hairol Azhar Abdul Kadir Jan 19, 2020 2:58AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Bullish sentiment.
Reply
0 0
Report
Petar Petrov
Petar Petrov Jul 15, 2019 2:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why is going so low???
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email